Literature DB >> 12475388

Modulation of the peroxisomal gene expression pattern by dehydroepiandrosterone and vitamin D: therapeutic implications.

M Depreter1, J Vandesompele, M Espeel, F Speleman, F Roels.   

Abstract

Peroxisomes are ubiquitous organelles required for several metabolic functions. Their dysfunction is responsible for a group of human inherited disorders. In the search for endogenous factors regulating the peroxisomal compartment in normal liver, we treated female rats with dehydroepiandrosterone (DHEA) and 25-hydroxycholecalciferol for 1 and 6 days. Relative transcription levels of 39 selected genes were evaluated by real-time quantitative RT-PCR analysis. Catalase (peroxisomal marker)-specific activity was assayed in total liver homogenate and peroxisomes were visualized by catalase localization. DHEA induced peroxisome proliferation and raised catalase specific activity. Expression levels of 16 (of which 11 were peroxisomal) genes were altered. Pex 11, acyl-CoA oxidase,l - andd -multifunctional enzyme, thiolase 1, phytanoyl-CoA hydroxylase, 70 kDa peroxisomal membrane protein and very long chain acyl-CoA synthetase were upregulated, three others were downregulated. Vitamin D caused downregulation of six genes. Administration of vitamin D to peroxisomal disorder patients may be contraindicated. The adrenocortical hormone DHEA is a potential natural regulator of the peroxisomal compartment. Its therapeutic use in X-linked adrenoleukodystrophy, some other beta-oxidation defects and classical Refsum should be considered.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12475388     DOI: 10.1677/joe.0.1750779

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  6 in total

1.  Adrenal steroids in adrenomyeloneuropathy. Dehydroepiandrosterone sulfate, androstenedione and 17alpha-hydroxyprogesterone.

Authors:  Maria Wichers-Rother; Andreas Grigull; Piotr Sokolowski; Birgit Stoffel-Wagner; Wolfgang Köhler
Journal:  J Neurol       Date:  2005-12       Impact factor: 4.849

2.  DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression.

Authors:  Shichun Zheng; E Andres Houseman; Zachary Morrison; Margaret R Wrensch; Joseph S Patoka; Christian Ramos; Daphne A Haas-Kogan; Sean McBride; Carmen J Marsit; Brock C Christensen; Heather H Nelson; David Stokoe; Joseph L Wiemels; Susan M Chang; Michael D Prados; Tarik Tihan; Scott R Vandenberg; Karl T Kelsey; Mitchel S Berger; John K Wiencke
Journal:  Neuro Oncol       Date:  2011-03       Impact factor: 12.300

3.  Feasibility of a liver transcriptomics approach to assess bovine treatment with the prohormone dehydroepiandrosterone (DHEA).

Authors:  Jeroen C W Rijk; Ad A C M Peijnenburg; Peter J M Hendriksen; Johan M Van Hende; Maria J Groot; Michel W F Nielen
Journal:  BMC Vet Res       Date:  2010-09-16       Impact factor: 2.741

4.  Selection of reference genes in different myocardial regions of an in vivo ischemia/reperfusion rat model for normalization of antioxidant gene expression.

Authors:  Nicoletta Vesentini; Cristina Barsanti; Alessandro Martino; Claudia Kusmic; Andrea Ripoli; AnnaMaria Rossi; Antonio L'Abbate
Journal:  BMC Res Notes       Date:  2012-02-29

5.  Phenylbutyrate up-regulates the adrenoleukodystrophy-related gene as a nonclassical peroxisome proliferator.

Authors:  Catherine Gondcaille; Marianne Depreter; Stéphane Fourcade; Maria Rita Lecca; Sabrina Leclercq; Pascal G P Martin; Thierry Pineau; Françoise Cadepond; Martine ElEtr; Nathalie Bertrand; Alain Beley; Sandrine Duclos; Dirk De Craemer; Frank Roels; Stéphane Savary; Maurice Bugaut
Journal:  J Cell Biol       Date:  2005-04-04       Impact factor: 10.539

6.  A spontaneous animal model of intestinal dysmotility evoked by inflammatory nitrergic dysfunction.

Authors:  Tatsuhiro Masaoka; Tim Vanuytsel; Christophe Vanormelingen; Sebastien Kindt; Shadea Salim Rasoel; Werend Boesmans; Gert De Hertogh; Ricard Farré; Pieter Vanden Berghe; Jan Tack
Journal:  PLoS One       Date:  2014-05-12       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.